(Q73445145)
Statements
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure (English)
scientific article published on 01 February 2000
No description defined